Eli Lilly and Eisai's battle to secure NHS reimbursement for their Alzheimer's disease therapies is dragging on, with guidance blocking use of the drug set for another review. After a successful ...

The streamlined framework is part of the UK Government’s plans to ensure the life sciences sector reaches its full potential.

As a practising surgeon, I know how important it is that patients get access to the latest treatments as quickly as possible. That’s why we’re cutting red tape so safe and effective new medicines can ...

The government hopes to limit cases in which NICE determines a treatment isn't cost effective after the MHRA has deemed it ...

In England, the appraisal process for new services and medicines is governed by the National Institute for Health and Care Excellence (NICE). NHS England is legally obliged to fund and resource ...

GPs are to be given a new non-hormonal prescribing option for menopausal hot flushes and night sweats, as NICE has expressed its support for fezolinetant. Final NICE draft guidance issued today ...

NHS watchdog to review evidence on two pioneering Alzheimer’s drugs - Donanemab and lecanemab were licensed for use in the UK in 2024 but were not made available on the NHS after Nice deemed their ben ...

Background Pharmacotherapy combinations have been shown to improve survival and reduce hospitalisations in adults with ...